The Ministry of Health and Family Welfare published a draft Gazette notification (28 June 2026) to amend the Medical Devices Rules, 2017 and shorten manufacturing-licence timelines.
Class B devices (e.g. BP monitors, pulse oximeters): licence timeline proposed to fall from 140 to 115 days; Class C and D (e.g. cardiac stents, hip/knee implants): from 105 to 90 days.
Stage-wise timelines are proposed for scrutiny, notified-body audit, compliance verification and licence issue; the draft is open for stakeholder comments via the Gazette and CDSCO website.
National regulator for drugs, cosmetics and medical devices; Central Licensing Authority under MDR 2017; six zonal offices and seven laboratories
Heads CDSCO; licensing authority for Class C/D manufacture and all device imports; CDSCO lists Rajeev Singh Raghuvanshi as DCGI
Third-party auditors accredited by NABCB (Quality Council of India) and registered with the Central Licensing Authority; audit Quality Management Systems at Class A (sterile/measuring) and Class B manufacturing sites
State drug controllers; grant manufacturing licences for Class A and B devices after notified-body audit
Parent Act; MDR 2017 are framed under its Section 33 (rule-making power); CDSCO and the DCGI regulate under it
First device-specific rulebook separating devices from drug rules; risk-based classes A-D; split of central vs state licensing; statutory processing timelines — the ones this draft shortens
Approved by Union Cabinet 19 April 2023, notified by the Department of Pharmaceuticals 2 May 2023; grow the sector from about $11 billion (2022) to $50 billion by 2030
Key: Six strategy areas, the first being regulatory streamlining — the goal this draft serves; others: infrastructure, R&D/innovation, investment, human resources, brand positioning
Boost domestic manufacturing; outlay Rs 3,420 crore, FY2020-21 to 2026-27
Key: Four target segments: cancer care/radiotherapy, radiology and imaging, anaesthetics and cardio-respiratory devices, implants
Common infrastructure for device manufacturers
Key: Four parks — Himachal Pradesh, Madhya Pradesh, Tamil Nadu, Uttar Pradesh — Rs 100 crore support each
GS Paper 2 > Health > Regulation of drugs and medical devices; GS Paper 3 > Industrial policy
General Awareness > Government bodies and policies
India's ranking in the 'Ease of Doing Business Index' is sometimes seen in the news. Which of the following has declared that ranking?
Answer: World Bank
Which one of the following is not a sub-index of the World Bank's Ease of Doing Business Index?
Answer: Maintenance of law and order
NABCB-accredited third-party auditor registered with CDSCO that checks a manufacturer's quality management system under MDR 2017.
The DCGI/CDSCO: licenses Class C and D manufacture and all device imports.
Devices graded A (lowest) to D (highest) risk; stricter control for higher classes.